1. Beutels P, Blommaert A, Hanquet G, Bilcke J, Thiry N, Sabbe M, et al. Cost-effectiveness of 10- and 13-valent pneumococcal conjugate vaccines in childhood. Health Technology Assessment (HTA). Brussels: Health Care Knowledge Centre (KCE) Report 155C; 2011.
2. Desmet S, Lagrou K, Wyndham-Thomas C, Braeye T, Verhaegen J, Maes P, et al. Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study. Lancet Infect Dis. 2021;21(1):127–36.
3. Gezondheidsraad H. Advies van de Hoge Gezondheidsraad nr. 8813. Vaccinatie van kinderen en adolescenten tegen pneumokokken. 2015. https://www.health.belgium.be/nl/advies8813-vaccinatie-pneumokokken-kinderen-fiche. Accessed 13 Jan 2021.
4. Gezondheidsraad H. Vaccinatie tegen pneumokokken - kinderen en adolescenten (HGR 9519) 2018. https://www.health.belgium.be/en/node/34691#anchor-34691. Accessed 13 Jan 2021.
5. Hanquet G, Lernout T, Vergison A, Verhaegen J, Kissling E, Tuerlinckx D, et al. Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges. Vaccine. 2011;29(16):2856–64.